{"title":"Covid-19 Tanısı alan hastalarda tedavi ve klinik deneyimler","authors":"İ. Yildiz, İlkay Bahçeci̇","doi":"10.38175/phnx.1240296","DOIUrl":null,"url":null,"abstract":"Purpose : All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic. \nMaterials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/ortomography findings were compatible between March 11 and May 31, 2020 were included in the study. \nResults: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of Diabetes Mellitus, Hypertansion and lung disease, and CT findings (p","PeriodicalId":134281,"journal":{"name":"Phoenix Medical Journal","volume":"178 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phoenix Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.38175/phnx.1240296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Covid-19 Tanısı alan hastalarda tedavi ve klinik deneyimler
Purpose : All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic.
Materials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/ortomography findings were compatible between March 11 and May 31, 2020 were included in the study.
Results: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of Diabetes Mellitus, Hypertansion and lung disease, and CT findings (p
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
